Key result
Early combined antiplatelet therapy with clopidogrel and aspirin within the first 24 hours for up to 90 days is an effective strategy for secondary prevention in patients with minor non-cardioembolic stroke or TIA.
Why the study?
Does antiplatelet therapy prevent recurrent stroke and cardiovascular events in patients with non-cardioembolic ischemic stroke or TIA?
Does antiplatelet therapy prevent recurrent stroke and cardiovascular events in patients with non-cardioembolic ischemic stroke or TIA?
Early short-term dual antiplatelet therapy is recommended for secondary prevention in patients with high-risk TIA or minor non-cardioembolic ischemic stroke.
Supports early short-term DAPT for high-risk TIA/minor stroke; leaves open optimal duration and selection criteria for trials.
The review shows modern concepts on the role of antiplatelet therapy in the secondary prevention of cardiovascular diseases in patients after non-cardioembolic ischemic stroke or transient ischemic attack (TIA). We present an analytical characteristic of all antiplatelet agents that have been studied in randomized controlled trials worldwide. We demonstrate the advantages and disadvantages of each agent in monotherapy and in combination. New ideas about the rationality of the use of combined antiplatelet therapy with clopidogrel and acetylsalicylic acid in the first 24 hours and no more than 90 days in patients with minor ischemic stroke or TIA are discussed. The efficacy and safety of new antiplatelet agents are analyzed. The basic principles of choosing antiplatelet agents in patients after ischemic noncardioembolic stroke/TIA are outlined.
No takes yet. Share an insight, caveat, or question.
Fonyakin et al. (2021) conducted a review in Non-cardioembolic ischemic stroke or transient ischemic attack (TIA). Antiplatelet therapy (aspirin, clopidogrel, ticagrelor, dipyridamole) was evaluated. Early combined antiplatelet therapy with clopidogrel and aspirin within the first 24 hours for up to 90 days is an effective strategy for secondary prevention in patients with minor non-cardioembolic stroke or TIA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: